STC1 is associated with tumor progression and suppressive niches in laryngeal squamous cell carcinoma Authors: Xiaoxue Chen, Wenjing Li, Yiyao Liu, Lei Zhang, Zhigang Zhao, Yue Wang, Linli Tian Published: 2026 ABSTRACT AbstractBackgroundLaryngeal squamous cell carcinoma (LSCC) exhibits high recurrence and therapy resistance. We aimed to investigate the undefined role of Stanniocalcin-1 (STC1) in LSCC pathogenesis.MethodsThe single-cell RNA sequencing (RNA-seq) data and the clinical information of LSCC patients were acquired from the public database. Prognostic differences and diagnostic efficiency of STC1 were assessed. The gene correlation was investigated by Spearman method. Enrichment analysis was performed using clusterProfiler, and immune infiltration was assessed with CIBERSORT. Finally, we analyzed the distribution of specific STC1 expression in cell types using single-cell RNA sequencing (scRNA-seq) analysis, and cell communication for ligand-receptor interactions between STC1+ cells and T cell subsets.ResultsThe upregulated STC1 was linked to tumor metastasis and disease stage in LSCC. It correlated with genes involved in extracellular matrix (ECM) remodeling, epithelial-mesenchymal transition (EMT), phosphoinositide 3-kinase (PI3K)-protein kinase B (Akt), and epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) resistance. High STC1 expression was linked to an immunosuppressive microenvironment, with increased M0 macrophages and reduced CD8+ T cells, and was positively correlated with the immune checkpoints [programmed death-ligand 1 (PD-L1), cytotoxic T-lymphocyte-associated protein 4 (CTLA4), T cell immunoglobulin and ITIM domain (TIGIT), T cell immunoglobulin and mucin domain-containing protein 3 (TIM-3)]. Single-cell analysis localized STC1 to epithelial cells, with STC1+ epithelial cells showing enriched endoplasmic reticulum (ER) stress, inflammatory signaling, and EMT during carcinogenesis. Cell-cell communication analysis revealed that STC1+ epithelial cells engage T cell subsets through more ligand-receptor pairs in the transforming growth factor-beta (TGF-β) and B- and T-lymphocyte attenuator (BTLA) pathways compared to STC1− epithelial cells.ConclusionsThese findings indicate STC1 is strongly correlated with signatures of immune evasion and malignant progression in LSCC, suggesting that targeting STC1 may reprogram the immunosuppressive microenvironment and improve therapeutic outcomes.Keywords: Laryngeal squamous cell carcinoma (LSCC), Stanniocalcin-1 (STC1), tumor microenvironment (TME), single-cell RNA sequencing (scRNA-seq), immune checkpoint Highlight box Key findings • In laryngeal squamous cell carcinoma (LSCC), Stanniocalcin-1 (STC1) overexpression correlates with advanced tumor stage, inferior overall survival, epithelial-mesenchymal transition (EMT), extracellular matrix (ECM) remodeling and epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) resistance signatures. • STC1-positive epithelial cells co-express immunosuppressive IDO1 and mediate stronger inhibitory ligand-receptor crosstalk with intratumoral T cell subsets via transforming growth factor-beta (TGF-β) and B- and T-lymphocyte attenuator (BTLA) pathways. • Multi-omics integrative analyses including bulk RNA sequencing, single-cell transcriptomics and immune deconvolution verify STC1 as a core driver shaping immunosuppressive tumor microenvironment in LSCC. What is known and what is new? • Previous studies have separately confirmed the oncogenic function of STC1 in multiple solid tumors, as well as the independent contributions of EMT, ECM remodeling and immune checkpoint molecules to LSCC progression and targeted drug resistance. • This study systematically maps the cellular source of STC1 in laryngeal lesions at single-cell resolution, establishes the intrinsic correlation between STC1 and a full spectrum of immunosuppressive checkpoints [programmed death-ligand 1 (PD-L1), cytotoxic T-lymphocyte-associated protein 4 (CTLA4), T cell immunoglobulin and ITIM domain (TIGIT), T cell immunoglobulin and mucin domain-containing protein 3 (TIM-3)], and clarifies that STC1+ epithelial cells dominate the intercellular inhibitory communication with T lymphocytes to facilitate tumor immune evasion. What is the implication, and what should change now? • This research highlights STC1 as a promising therapeutic target to simultaneously reverse local immunosuppression and overcome EGFR-TKI resistance in LSCC. • STC1 expression level deserves prospective clinical validation as an auxiliary biomarker for prognostic risk stratification, which may guide individualized combined regimens integrating targeted therapy and immune checkpoint blockade. Introduction Laryngeal squamous cell carcinoma (LSCC) is the second most common malignancy of the head and neck region, accounting for approximately 25–30% of all head and neck squamous cell carcinomas (HNSCC) (1). Despite therapeutic advances, prognosis for advanced or recurrent LSCC remains dismal (2). A major clinical challenge lies in the high rates of locoregional recurrence, metastasis, and intrinsic or acquired resistance to conventional treatments (3,4), including platinum-based chemotherapy and epidermal growth factor receptor (EGFR) inhibitors (erlotinib and gefitinib) (5). Moreover, the immunosuppressive tumor microenvironment (TME) in LSCC often limits the efficacy of emerging immune checkpoint blockade therapies (6). Thus, identifying molecular signatures associated with tumor severity and drivers of treatment resistance is critically needed. Stanniocalcin-1 (STC1) is a conserved secreted glycoprotein, originally identified for its role in calcium and phosphate homeostasis (7,8). In mammals, STC1 is ubiquitously expressed and functions as a pleiotropic modulator of stress responses, including endoplasmic reticulum (ER) and oxidative stress (9). Accumulating evidence implicates STC1 in tumorigenesis across multiple cancer types (10). It promotes cancer cell survival by inhibiting apoptosis (11), enhances angiogenesis through VEGF signaling (12), and drives epithelial-mesenchymal transition (EMT) (13), supporting invasion and metastasis. Notably, STC1 has been shown to remodel the extracellular matrix (ECM), activate pro-survival pathways [e.g., phosphoinositide 3-kinase (PI3K)-protein kinase B (Akt) and transforming growth factor-beta (TGF-β)] (14) and contribute to resistance against chemotherapy and targeted therapies (15). Beyond its tumor-intrinsic roles, STC1 also shapes the immune landscape of the TME: it correlates with immunosuppressive cell infiltration (e.g., M2-like macrophages) (16,17), downregulates cytotoxic T cell activity, and positively associates with immune checkpoint molecules [e.g., programmed death-ligand 1 (PD-L1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA4)] (18). Elevated STC1 expression has been linked to poor prognosis in cancers of the breast, lung, liver, and colorectum, positioning it as both a potential diagnostic biomarker and a mediator of aggressive tumor biology (19). However, its expression pattern, cellular sources, and functional relevance in LSCC remain largely unexplored. Given the established involvement of STC1 in tumor progression, immune modulation, and therapy resistance across multiple cancer types, its potential role in LSCC warrants systematic investigation. This study integrated bulk RNA sequencing (RNA-seq) from The Cancer Genome Atlas (TCGA) and single-cell RNA-seq from GSE206332 to characterize STC1 expression, clinical relevance, cellular origin, and associated molecular programs. Analyses included associations with clinicopathological features, pathway enrichment, immune cell infiltration, and cell communication, along with transcriptional dynamics in STC1+ epithelial cells. Our study showed that high STC1 expression is associated with poor prognosis. STC1 levels positively correlate with the expression of immune checkpoint molecules PD-L1, CTLA4, and T cell immunoglobulin and ITIM domain (TIGIT). Moreover, STC1+ epithelial cells exhibit stronger suppressive interactions with T cell subsets compared to STC1− cells. We present this article in accordance with the STROBE reporting checklist (available at https://tcr.amegroups.com/article/view/10.21037/tcr-2026-1080/rc). Methods Data collection RNA-seq and clinical information (age, sex, stage, follow-up) for 117 laryngeal carcinomas and 12 normal tissues were sourced from TCGA-HNSC via the GDC Portal (https://portal.gdc.cancer.gov/). Additionally, the single-cell RNA sequencing (scRNA-seq) dataset GSE206332 from Gene Expression Omnibus (GEO, https://www.ncbi.nlm.nih.gov/gds) database was downloaded, including 3 normal laryngeal mucosa, 3 carcinomas in situ, and 2 margins of cancer samples. The library was prepared using the 3’ droplet-based 10× Genomics platform, and sequencing was performed on the Illumina NextSeq 500 platform. The study was conducted in accordance with the Declaration of Helsinki and its subsequent amendments. Receiver operating characteristic (ROC) curve The diagnostic performance of STC1 was evaluated using the pROC R package (8), the roc function was applied to construct an object based on the transcripts per million (TPM) of STC1 in LSCC and normal tissues, then the plot function was used to draw the ROC curve and calculate the area under the curve (AUC) value, the optimal cut-off point, and the 95% confidence interval. Survival analysis For Kaplan-Meier analysis, the optimal STC1 cut-off was determined with surv_cutpoint function and survival differences were tested by log-rank test in survminer R package. For multivariate Cox regression, we used the coxph function from the survival package to estimate hazard ratios (HRs) and P values for STC1 along with clinical covariates, including age, sex, tumor-node-metastasis (TNM) stage, and pathological stage in relation to overall survival in the TCGA-HNSC cohort. Forest plots were generated using the ggforest function. Screening and enrichment analysis of STC1 positively correlated genes Spearman correlation analysis was used to identify protein-coding genes strongly positively correlated with STC1 in bulk RNA-seq data (r>0.5, P<0.05). Functional enrichment of these genes was performed using clusterProfiler, with significant Gene Ontology (GO) biological processes and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways defined by adjusted P<0.05. Immune infiltration analysis We applied the CIBERSORT deconvolution algorithm (20,21) to infer the relative infiltration proportions of 22 immune cell types in each LSCC sample, excluding samples with P value >0.05. Spearman correlation coefficients were then calculated between STC1 expression levels and 22 immune cell types. Drug sensitivity analysis Half maximal inhibitory concentration (IC50) values for gefitinib and erlotinib in each LSCC sample were predicted via pRRopheticPredict function in pRRophetic package (22,23). Lower IC50 values indicate higher drug sensitivity. Single-cell atlas Data were processed by “Seurat” R package (24); cells (200< gene number <6,000, mitochondrial content <20% and hemoglobin expression <1%) were retained. The CellCycleScoring function for cell cycle scores, NormalizeData function for normalization (normalization.method = “LogNormalize”, scale.factor =10,000), and FindVariableFeatures function for top 3,000 highly variable genes, ScaleData function [vars.to.regress = c(“nCount_RNA”, “percent.mito”, “percent.HB”, “S.Score”, “G2M.Score”)] for data scaling were performed. Next, principal component analysis (PCA) was conducted after Harmony-based batch removal (max_iter =20, lambda =0.5). Uniform manifold approximation and projection (UMAP) visualization and clustering were performed using FindNeighbors, RunUMAP and FindClusters functions (resolution =0.1 for whole-cell clustering and 0.2 for T cell subclustering) based on top20 principal components. Clusters were annotated by CellMarker 2.0 (http://117.50.127.228/CellMarker/). We classified epithelial cells into STC1+ and STC1− subsets based on STC1 expression, differentially expressed genes (DEGs) between STC1+ and STC1− epithelial cells were identified using the FindMarkers function (|log2fold change (FC)| >0.5 and adjusted P value <0.05). Cancer-related hallmark activity in epithelial cells Pathway RespOnsive GENes for activity (PROGENy) inferred pathway activity based on “footprint” gene sets derived from large-scale perturbation experiments, representing the top 100 most responsive genes for each of 14 cancer-relevant signaling pathways. Pathway activity scores were computed as the weighted sum of gene expression multiplied by these weights (25). In this study, the core PROGENy genes and their weights for human pathways were obtained using the get_progeny function from the “decoupleR” package, and pathway scores of epithelial cells were analyzed via run_mlm function. Gene set enrichment analysis (GSEA) All genes were ranked by log2FC from STC1+ versus STC1− epithelial cells in descending order. GSEA was performed using the fgsea package (26), and gene set in MSigDB database (https://www.gsea-msigdb.org/gsea/msigdb/index.jsp), setting minSize =15, maxSize =500, nperm =10,000 to assess pathway enrichment in STC1+ epithelial cells. Enrichment plots for selected pathways were generated using the plotEnrichment function. Cell communication analysis Cell communication among STC1+ epithelial cells, STC1− epithelial cells, and T cell subsets was analyzed using the CellChat package (27). We constructed a CellChat object via createCellChat and CellChatDB.human database. The identifyOverExpressedGenes and identifyOverExpressedInteractions function was used for cell interactions analysis. Ligand-receptor pairs were analyzed via projectData. Communication probabilities were inferred with computeCommunProb, and pathway-level communication networks were reconstructed using computeCommunProbPathway. Finally, the interest ligand-receptor interactions between STC1+/STC1− epithelial cells and T cell subsets were visualized as bubble plots for selected signaling pathways using netVisual_bubble. Statistical analysis R (v4.4.1) was employed in data analysis, with the Wilcoxon rank-sum test for group comparisons, Spearman’s method for correlations, and the log-rank test for survival differences, with P<0.05 considered significant. Results The association between STC1 expression and clinical features in LSCC We analyzed the STC1 expression and found that STC1 was significantly higher in tumor tissue (Figure1A), and ROC curve exhibited high diagnostic efficiency (AUC =0.793) (Figure 1B). Notably, patients highly expressing STC1 had worse prognosis (Figure 1C). Meanwhile, the STC1 expression generally increased with advancing T, N and pathological stage (Figure 1D-1H). However, multivariate Cox analysis did not support STC1 as an independent prognostic factor (Figure 1I, P=0.052). Clinical relevance analysis of STC1 in LSCC. (A) The difference of STC1 in tumor and control samples. (B) ROC analysis for the diagnostic performance of STC1. The optimal cutoff value calculated by the Youden‑index was 8.906, with a corresponding sensitivity of 0.833 and specificity of 0.812. (C) Kaplan-Meier survival analysis for patients in high and low-STC1 expression groups. (D) STC1 expression difference in T stages. (E) STC1 expression difference in N stages. (F) STC1 expression difference in M stages. (G) STC1 expression difference in different pathological stages. (H) STC1 expression difference in different genders. (I) Forest plot of multivariate Cox analysis among STC1 and clinical features. **, P<0.01; ***, P<0.001. AIC, Akaike information criterion; AUC, area under the curve; CI, confidence interval; LSCC, laryngeal squamous cell carcinoma; M, metastasis; N, node; ROC, receiver operating characteristic; STC1, Stanniocalcin-1; T, tumor; TPM, transcripts per million. STC1-linked biological processes and immune cells Subsequently, correlation analysis revealed that the highly positive correlation of STC1 and SLC2A3, ADAMTS4, and S1PR3 genes (Figure 2A). These genes were significantly enriched in ECM organization, angiogenesis regulation, and EMT biological processes (Figure 2B), with significant involvement in the PI3K-Akt, TGF-β signaling pathways, and EGFR tyrosine kinase inhibitor (TKI) resistance (Figure 2C). Immune profiling revealed that STC1 levels positively associated with M0 macrophages and memory resting CD4 T cells, yet negatively correlated with CD8+ T and plasma cells (Figure 2D). The median value of STC1 divided patients into two groups, a lower CD8+ T cell infiltration was observed in the STC1-high group (Figure 2E). To further assess the potential link between STC1 and EGFR-TKI resistance, we further assessed the IC50 of candidate drugs using pRRophetic package; the gefitinib IC50 was significantly elevated in the STC1-high group (Figure 2F). The STC1-high group exhibited a trend toward higher erlotinib IC50 values than the STC1-low group, though not statistically significant (P=0.13, Figure 2G). Functional enrichment, immune infiltration, and drug sensitivity of STC1. (A) Top 10 genes most positively correlated with STC1 expression. (B) Biological processes enriched among STC1 positively correlated genes. (C) KEGG pathways enriched among STC1 positively correlated genes. (D) Correlation between STC1 expression and infiltration levels of immune cells. (E) The difference of CD8+ T cell infiltration in high and low STC1 expression patients. (F) IC50 values of gefitinib in STC1-high versus STC1-low groups. (G) IC50 values of erlotinib in STC1-high versus STC1-low groups. IC50, half maximal inhibitory concentration; KEGG, Kyoto Encyclopedia of Genes and Genomes; STC1, Stanniocalcin-1. STC1 was positively correlated with several checkpoints To investigate the underlying role of STC1 in the TME of LSCC, we next assessed its correlation with immune checkpoint molecules. STC1 expression showed strong positive correlations with PD-L1, CTLA4, TIGIT, and TIM-3 (all P<0.05), while STC1 showed non-significant positive correlations with programmed death-1 (PD-1) and lymphocyte activation gene-3 (LAG3) (Figure 3), implicating STC1 in immune evasion. Correlation between STC1 expression and immune checkpoint-related genes. CTLA4, cytotoxic T-lymphocyte-associated protein 4; PD-1, programmed death-1; PD-L1, programmed death-ligand 1; LAG3, lymphocyte activation gene-3; STC1, Stanniocalcin-1; TIGIT, T cell immunoglobulin and ITIM domain; TIM-3, T cell immunoglobulin and mucin domain-containing protein 3. STC1 was expressed in a subset of epithelial cells and was associated with tumor progression To map the cellular sources of STC1 in laryngeal carcinogenesis, we analyzed scRNA-seq data from GSE206332. Unsupervised clustering identified seven major populations, including epithelial cells (KRT15/DEFB1), NK/T cells (CD3D/NKG7+), macrophages (C1QB/LYZ/AIF1), neutrophils (BCL2A1/GOS2), fibroblasts (LUM/COL1A2/MGP), B cells (BANK1/MS4A1) and plasma B cells (DERL3/MZB1/IGLL5) (Figure 4A,4B). The proportion of epithelial cells was less than in carcinoma in situ and tumor margins compared to normal laryngeal mucosa, whereas NK/T cells and neutrophils were more abundant in these regions (Figure 4C). STC1 was specifically expressed in fibroblasts and epithelial subpopulations (Figure 4D), which also co-expressed IDO1 (a key immunosuppressive mediator) (Figure 4E), implicating STC1 in immune evasion. Given the low proportion of fibroblasts in carcinoma in situ and tumor margins, we focused our subsequent analyses on epithelial cells. Notably, we stratified epithelial cells based on STC1 expression and found that the STC1-high subpopulation exhibited significantly elevated STC1 levels in carcinoma in situ compared to normal mucosa (Figure 4F), suggesting its involvement in early tumor progression. Single-cell RNA sequencing analysis. (A) UMAP visualization of unsupervised cell clustering, with major cell populations labeled. (B) Bubble plot showing expression of canonical marker genes. (C) Stacked bar plot depicting the cell type. (D,E) UMAP of STC1 and IDO1 expression levels across all cells. (F) Bubble plot and violin plot showing STC1 expression levels in STC1-high epithelial cell subpopulations across normal mucosa, carcinoma in situ, and cancer margins. STC1, Stanniocalcin-1; UMAP, uniform manifold approximation and projection. Biological processes associated with STC1+ epithelial cells To further characterize the biological functions associated with STC1+ epithelial cells, we classified epithelial cells into STC1+ and STC1− subsets based on STC1 expression and applied PROGENy to infer activity across 14 canonical cancer-related signaling pathways. STC1+ epithelial cells exhibited significantly higher scores for Janus kinase-signal transducer and activator of transcription (JAK-STAT), tumor necrosis factor (TNF)-α, and phosphoinositide 3-kinase (PI3K) pathways compared to their STC1− counterparts (Figure 5A). A set of DEGs in STC1+/STC1− groups was obtained (Figure 5B), they were enriched for functions related to ER stress, TNF response, and positive regulation of EMT (Figure 5C), and pathways involving reactive oxygen species (ROS) metabolism, ferroptosis, and cellular senescence (Figure 5D). Consistent with this, there was no significant EMT enrichment via GSEA in STC1+ epithelial cells [normalized enrichment score (NES) =0.9098, P=0.67, adjusted P=0.80, Figure 5E]. Notably, key EMT-associated genes, including MDK, WWTR1, OLFM1, and GCNT2, were significantly elevated in STC1+ relative to STC1− epithelial cells (Figure 5F, P<0.05). Biological roles of STC1+ epithelial cells in LSCC. (A) Box plot showing PROGENy pathway scores between STC1+ and STC1−epithelial cells. (B) Volcano plot showing differential expression analysis between STC1+ and STC1− epithelial cells. (C) Biological processes enriched among upregulated differentially expressed genes in STC1+ epithelial cells. (D) KEGG pathways enriched among upregulated differentially expressed genes in STC1+ epithelial cells. (E) GSEA enrichment scores for epithelial-mesenchymal transition in STC1+ versus STC1− epithelial cells. (F) Violin plots comparing the expression levels of representative EMT-associated genes between STC1+ epithelial cells and STC1− epithelial cells. EMT, epithelial-mesenchymal transition; GSEA, gene set enrichment analysis; KEGG, Kyoto Encyclopedia of Genes and Genomes; LSCC, laryngeal squamous cell carcinoma; NES, normalized enrichment score; PROGENy, Pathway RespOnsive GENes for activity; STC1, Stanniocalcin-1. STC1+ epithelial cells drove immunosuppressive crosstalk with T subpopulations in LSCC Finally, to assess how STC1+ and STC1− epithelial cells differentially communicate with T cell subsets in LSCC, we re-clustered NK/T cells in carcinoma in situ into five distinct subpopulations (Figure 6A) and annotated each by canonical marker genes (Figure 6B). Using CellChat, we then modeled ligand-receptor interactions between epithelial subsets and T cell clusters. STC1+ epithelial cells engaged in more ligand-receptor pairs with T cells than STC1− cells (Figure 6C), driven in part by significantly higher expression of PD-L1 (Figure 6D, P<2.2e-16), a finding suggestive of enhanced capacity to suppress T cell function. Notably, STC1+ epithelial cells also showed increased interaction strength through the TGF-β and B- and T-lymphocyte attenuator (BTLA) signaling axes, with more ligand-receptor pairs targeting T cell subsets via these immunosuppressive pathways (Figure 6E,6F). Cell communication analysis. (A) UMAP visualization of NK/T cell subpopulations. (B) Violin plots showing expression of canonical marker genes of NK/T subpopulation. (C) Interaction network between STC1+/STC1− epithelial cells and T cell subsets of carcinoma in situ, with numbers indicating the count of ligand–receptor pairs. (D) Comparison of CD274 (PD-L1) expression between STC1+ and STC1− epithelial cells. (E) Bubble plot of ligand-receptor interactions between STC1+ and STC1− epithelial cells affecting T cell subsets via the TGF-β pathway. (F) Bubble plot illustrating ligand-receptor interactions of STC1+ and STC1− epithelial cells impacting T cell subsets through the BTLA pathway. BTLA, B- and T-lymphocyte attenuator; PD-L1, programmed death-ligand 1; STC1, Stanniocalcin-1; TGF-β, transforming growth factor-beta; UMAP, uniform manifold approximation and projection. Single-cell verification of direct crosstalk between STC1+ epithelial cells and CD8+ T-like subsets To validate the putative direct crosstalk between STC1+ epithelial cells and CD8+ T cells implied by bulk CIBERSORT deconvolution, reannotation of all NK/T subpopulations and quantification of CD8+ T cell signature scores were performed across five T/NK clusters: USMG5+ NKT cells, HAVCR2+ exhausted T cells, CCR7+ naive T cells, FOXP3+ regulatory T cells, and GZMK+ effector T cells (Figure S1A,S1B). USMG5+ NKT cells harbored the highest CD8 signature score and were assigned as a surrogate CD8+ T-like subset for downstream cell-cell communication profiling. CellChat-mediated ligand-receptor interaction analysis uncovered broad intercellular signaling between STC1+ epithelial cells and USMG5+ NKT cells, with antigen presentation-associated HLA-CD8A/CD8 ligand-receptor pairs substantially enriched within this cellular crosstalk (Figure S1C). Integration of these results with prior observations of PD-L1 upregulation and amplified TGF-β/BTLA immunosuppressive signaling supports a model where STC1+ malignant epithelial cells establish a dichotomous tumor immune microenvironment characterized by augmented antigen presentation alongside prevailing inhibitory signaling cascades. This dual-signal landscape ultimately induces CD8+ T cell dysfunction and facilitates tumor immune evasion. To independently verify the bulk-level association between STC1 expression and diminished intratumoral CD8+ T cell infiltration, signature-guided deconvolution of the TCGA-LSCC bulk transcriptome was conducted using cell-type-specific markers curated from single-cell datasets. Correlation testing revealed a significant inverse association between STC1 expression and the relative abundance of USMG5+ CD8+ NKT cells (Figure S1D), recapitulating initial CIBERSORT evidence of reduced CD8+ T cell infiltration in STC1-high LSCC patients. Collectively, single-cell intercellular communication profiling and cross-omic deconvolution results corroborate immunosuppressive crosstalk between STC1+ epithelial cells and CD8+ T cell subsets. Computational prediction linking STC1 expression to intrinsic immune checkpoint inhibitor (ICI) responsiveness Given the robust correlations between STC1 and a panel of immune checkpoint molecules, further assessment of the predictive value of STC1 expression for ICI response was performed via the Immunophenoscore (IPS) from The Cancer Immunome Atlas (TCIA), a validated computational signature quantifying tumor immunogenicity and intratumoral T cell activation capacity. Under simulated untreated (ips_ctla4_neg_pd1_neg) and single-agent CTLA-4 blockade (ips_ctla4_pos_pd1_neg) conditions, significantly reduced IPS values were detected in STC1-high patients relative to the STC1-low cohort (Figure S2A, P<0.01). Continuous correlation analyses further identified a prominent inverse association between STC1 abundance and IPS scores across these two therapeutic simulation groups (Figure S2B). While comparable IPS levels were noted between STC1 subgroups under PD-1 monotherapy or combined PD-1/CTLA-4 blockade, consistent negative correlative trends between STC1 expression and IPS persisted across all four ICI simulation modalities. Collectively, these computational predictions indicated that elevated STC1 levels correlate with attenuated tumor immunogenicity and suppressed intratumoral immune activation, a phenotype potentially conferring reduced ICI sensitivity in LSCC. When integrated with single-cell evidence documenting defective antigen presentation and amplified immunosuppressive ligand-receptor crosstalk in STC1+ epithelial cells, the data support a tight linkage between STC1 expression and intrinsic ICI responsiveness in LSCC. Discussion Emerging evidence points STC1 being more than just a stress-responsive protein, but as a potential orchestrator of the tumor-immune-stromal axis across multiple cancers (11). Notably, recent studies have documented conflicting, dual functional roles of STC1 in human malignancies. Specifically, multiple reports characterize STC1 as an oncogenic driver that accelerates metastasis, therapy resistance and intratumoral immune suppression in lung, gastric, hepatocellular and ovarian cancers, while a small subset of investigations describe STC1 as a tumor-suppressive factor capable of inhibiting proliferation and malignant progression in certain tumor subtypes (10,16). Such context-dependent functional divergence implies STC1’s biological effects are highly tissue-specific and shaped by unique TME characteristics. In line with this, a recent study by our group demonstrated that LSCC cells secrete STC1-containing exosomes that directly suppress T cell function and promote M2 macrophage polarization, implicating STC1 in shaping an immunosuppressive niche in LSCC (17). Using single-cell RNA-seq, another study revealed that malignant epithelial cells in LSCC drive an immunosuppressive microenvironment and exhibit stemness- and invasion-associated transcriptional reprogramming, highlighting their central role in tumor progression (6). However, whether STC1 contributes to the uniquely immunosuppressive and therapy-resistant landscape of LSCC remains unexplored. We provide a comprehensive characterization of STC1 in LSCC, integrating bulk transcriptomics, single-cell resolution profiling, and functional pathway analyses. Our findings revealed that STC1 is not only markedly elevated in LSCC and associated with advanced disease stage and poorer survival, but also intricately linked to extracellular remodeling, immunosuppression, and EGFR TKI resistance, highlighting its multifaceted role in LSCC progression. We further speculate on the potential molecular basis underlying STC1 upregulation in LSCC epithelial cells. Single-cell transcriptomic profiling confirmed predominant STC1 enrichment within malignant epithelial populations rather than stromal fibroblasts, and STC1+ epithelial subsets exhibited significantly elevated ER stress, inflammatory TNF-α signaling, and EMT transcriptional signatures. Chronic ER stress induced by persistent hypoxia, nutrient deprivation and inflammatory stimulation within the hypoxic LSCC microenvironment is widely recognized to trigger downstream stress-responsive transcription factors, which may transcriptionally activate STC1 expression (28,29). Additionally, aberrant activation of PI3K-Akt and TGF-β signaling cascades, which we found strongly correlated with STC1 levels in bulk LSCC tissues, can further amplify STC1 transcription and create a positive feedback loop to sustain its high expression in tumor epithelium. This microenvironment-driven transcriptional activation provides a plausible explanation for specific STC1 overexpression observed in laryngeal malignant lesions. Moreover, the elevated expression of STC1 and its strong diagnostic performance (AUC =0.793) support its potential for LSCC detection. Notably, STC1 expression increases progressively with T stage, N stage, and pathological stage, indicating its involvement in LSCC aggressive progression. Functionally, STC1-correlated genes were enriched in pathways central to cancer progression, including ECM organization, angiogenesis, EMT, and PI3K-Akt/TGF-β signaling (18,30). These observations align with prior reports in breast, gastric, and hepatocellular carcinomas, where STC1 promotes invasion and metastasis through ECM degradation and cytoskeletal reprogramming (31,32). Importantly, our data link STC1 to EGFR TKI resistance (33), as STC1-high tumors required significantly higher gefitinib concentrations for growth inhibition. This implies STC1 may drive resistance to both chemotherapy and EGFR inhibitors (34), particularly relevant in LSCC, where EGFR-targeted therapy often fails. Meanwhile, our data suggested that STC1 contributes to immune suppression in LSCC, the STC1 expression positively correlates with key immune checkpoint molecules (PD-L1, CTLA4, TIGIT, TIM-3) that promote immune resistance (35) and is associated with an immunosuppressive cellular landscape, including increased M0 macrophages and decreased CD8+ T cells (36). STC1 is not broadly expressed in laryngeal tumors but is specifically enriched in a malignant epithelial subpopulation that co-expresses IDO1, an enzyme that suppresses T cells through tryptophan catabolism (37). This co-localization suggests STC1 marks cells actively involved in immunosuppression, rather than passive inflammation. Consistently, CellChat analysis shows STC1+ epithelial cells engage T cell subsets more strongly through inhibitory axes (PD-L1, TGF-β, BTLA) (38), supporting active immune suppression. Overall, these observations indicate that STC1 is correlated with molecular signatures underlying potential immunotherapy responsiveness, and may serve as an auxiliary biomarker for evaluating combined therapeutic regimens containing EGFR inhibitors, immune checkpoint blockers and IDO1 inhibitors. Despite these insights, several limitations warrant acknowledgment. First, our findings rely primarily on retrospective bioinformatic analyses, the experimental validation is needed. Second, the scRNA-seq dataset includes only a small number of samples, which may limit the robustness of the identified epithelial and T cell subsets. Third, drug response data are inferred from computational models and direct in vitro or in vivo evidence linking STC1 to gefitinib resistance in LSCC remains to be demonstrated. Conclusions In conclusion, our study positions STC1 as a central node connecting tumor-intrinsic stress adaptation, stromal remodeling, and immune suppression in LSCC. While not yet an independent prognostic marker, its strong association with gefitinib resistance and immune checkpoint expression suggests that STC1 is correlated with molecular signatures underlying potential immunotherapy responsiveness, rendering it a companion biomarker and a candidate target for combination therapy, particularly in regimens combining EGFR inhibitors and immunotherapy. Future work should focus on mechanistic dissection of STC1-driven immunosuppression and preclinical testing of STC1-targeted interventions in LSCC. Supplementary The article’s supplementary files as Acknowledgments None. Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. The study was conducted in accordance with the Declaration of Helsinki and its subsequent amendments. Footnotes Reporting Checklist: The authors have completed the STROBE reporting checklist. Available at https://tcr.amegroups.com/article/view/10.21037/tcr-2026-1080/rc Funding: This work was supported by the Fundamental Research Funds for the Provincial Universities of Heilongjiang Province (Nos. 2025-KYYWF-ZR0168 and 2024-KYYWF-0176) and the Heilongjiang Province Postdoctoral Research Startup Fund (No. 21042240074). Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://tcr.amegroups.com/article/view/10.21037/tcr-2026-1080/coif). The authors have no conflicts of interest to declare. References Available at https://tcr.amegroups.com/article/view/10.21037/tcr-2026-1080/prf Supplementary Materials The article’s supplementary files as